HUE054500T2 - MET antitest hatóanyag konjugátumok - Google Patents

MET antitest hatóanyag konjugátumok

Info

Publication number
HUE054500T2
HUE054500T2 HUE17817374A HUE17817374A HUE054500T2 HU E054500 T2 HUE054500 T2 HU E054500T2 HU E17817374 A HUE17817374 A HU E17817374A HU E17817374 A HUE17817374 A HU E17817374A HU E054500 T2 HUE054500 T2 HU E054500T2
Authority
HU
Hungary
Prior art keywords
drug conjugates
antibody drug
met antibody
met
conjugates
Prior art date
Application number
HUE17817374A
Other languages
English (en)
Inventor
Yiqing Feng
Philip Arthur Hipskind
Renhua Li
Ling Liu
Takako Wilson
Aaron David Wrobleski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUE054500T2 publication Critical patent/HUE054500T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HUE17817374A 2016-11-23 2017-11-17 MET antitest hatóanyag konjugátumok HUE054500T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662425853P 2016-11-23 2016-11-23

Publications (1)

Publication Number Publication Date
HUE054500T2 true HUE054500T2 (hu) 2021-09-28

Family

ID=60703003

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17817374A HUE054500T2 (hu) 2016-11-23 2017-11-17 MET antitest hatóanyag konjugátumok

Country Status (15)

Country Link
US (1) US11167039B2 (hu)
EP (1) EP3544634B1 (hu)
JP (1) JP6951441B2 (hu)
CN (1) CN110022903B (hu)
CY (1) CY1124266T1 (hu)
DK (1) DK3544634T3 (hu)
ES (1) ES2875365T3 (hu)
HR (1) HRP20210922T1 (hu)
HU (1) HUE054500T2 (hu)
LT (1) LT3544634T (hu)
PL (1) PL3544634T3 (hu)
PT (1) PT3544634T (hu)
RS (1) RS61967B1 (hu)
SI (1) SI3544634T1 (hu)
WO (1) WO2018098035A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
CA3161919A1 (en) * 2020-09-01 2022-03-10 Remegen Co., Ltd. Anti-c-met antibody-drug conjugate and applications thereof
EP4288456B1 (en) 2021-02-03 2024-09-18 Mythic Therapeutics, Inc. Anti-met antibodies and uses thereof
JP2024515266A (ja) * 2021-04-08 2024-04-08 ビョンディス・ビー．ブイ． 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US8039273B2 (en) 2005-07-18 2011-10-18 Seattle Genetics, Inc. β-glucuronide-linker drug conjugates
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
SG194875A1 (en) 2011-05-08 2013-12-30 Legochem Biosciences Inc Protein-active agent conjugates and method for preparing the same
SG11201704458SA (en) 2014-12-08 2017-06-29 Sorrento Therapeutics Inc C-met antibody drug conjugate
CN114177308B (zh) * 2016-05-17 2024-07-09 艾伯维生物制药股份有限公司 抗cMet抗体药物偶联物及其使用方法

Also Published As

Publication number Publication date
CN110022903A (zh) 2019-07-16
CN110022903B (zh) 2022-06-03
WO2018098035A1 (en) 2018-05-31
ES2875365T3 (es) 2021-11-10
US11167039B2 (en) 2021-11-09
CY1124266T1 (el) 2022-07-22
PL3544634T3 (pl) 2021-09-27
EP3544634B1 (en) 2021-04-14
RS61967B1 (sr) 2021-07-30
PT3544634T (pt) 2021-06-02
DK3544634T3 (da) 2021-06-07
HRP20210922T1 (hr) 2021-09-03
JP6951441B2 (ja) 2021-10-20
SI3544634T1 (sl) 2021-08-31
JP2019536780A (ja) 2019-12-19
US20200061204A1 (en) 2020-02-27
EP3544634A1 (en) 2019-10-02
LT3544634T (lt) 2021-06-10

Similar Documents

Publication Publication Date Title
IL267003A (en) Multidrug antibody conjugates
IL290457A (en) Antibodies and their conjugates
IL265309A (en) Bispecific antibodies against MUC16 and CD3 and drug conjugates against MUC16
IL291073A (en) Drug conjugates of anti-egfr antibodies
IL263600B1 (en) Antibodies against b7–h3 and drug-antibody conjugates
HK1232123A1 (zh) 親水性抗體-藥物偶聯物
IL267834B1 (en) Conjugates of drug and antibody against ccr7
IL252015A0 (en) Antibody drug conjugates
IL250189A0 (en) Anti–cdh6 antibody drug conjugates
SG10202002153PA (en) Glycoengineered antibody drug conjugates
IL251938A0 (en) Antibodies against CS1 and antibody-drug conjugates
EP3250238A4 (en) Antibody drug conjugates
IL259651A (en) Conjugations between an antibody to a specific her2 site and a drug
IL274650A (en) Conjugate an antibody drug against CD40
EP3253212A4 (en) Antibody drug conjugates
EP3180388A4 (en) Polyoxazoline antibody drug conjugates
ZA202004675B (en) Pharmaceutical combinations comprising an anti-ly75 antibody
PT3544634T (pt) Conjugados anticorpo-fármaco anti-met
LU92659B1 (en) Glycooptimized antibody drug conjugates